Nonpolymerizable Fibrinogen for Thrombosis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for thrombosis often compromise hemostasis, and there is a need for a method to inhibit or reduce thrombosis risk without affecting hemostatic potential.
Innovation Solution
Administration of nonpolymerizable fibrinogen, which suppresses fibrin matrix formation differentially in arterial and venous thrombosis, thereby reducing thrombosis incidence and thrombus size while preserving hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antithrombotic therapies are used to reduce thrombosis risk, then thrombosis incidence is reduced, but hemostatic function is compromised
Solution Approach 1:
The patent applies local quality by creating a fibrinogen variant with site-specific modification: the polymerization site is blocked while other functional regions remain intact. This allows the protein to selectively inhibit fibrin matrix formation in thrombotic conditions while preserving hemostatic functions such as platelet aggregation and clot retraction, thus resolving the contradiction between thrombosis prevention and hemostasis maintenance
Solution Approach 2:
The patent employs parameter changes by modifying a specific property of fibrinogen (the polymerization capability) while maintaining other parameters unchanged. The E20Q mutation specifically alters the polymerization interface, preventing fibrin matrix assembly, while leaving the hemostatic functions of fibrinogen intact. This selective parameter modification enables differential suppression of thrombosis without compromising hemostasis
2Quantity of substance
If fibrinogen levels are reduced to suppress fibrin matrix formation, then thrombus size is reduced, but hemostatic potential is compromised
Solution Approach 1:
Instead of reducing overall fibrinogen quantity, the patent applies local quality by introducing a site-specific blockage in the polymerization domain of fibrinogen. This allows normal levels of fibrinogen to be present and functional for hemostasis, while the localized defect prevents pathological fibrin matrix formation. The E20Q mutation specifically targets the polymerization interface, leaving other functional domains intact
Solution Approach 2:
The patent uses the modified fibrinogen molecule as an intermediary that mediates between normal hemostatic function and suppression of pathological fibrin formation. The E20Q mutant fibrinogen acts as a dominant-negative inhibitor, binding to thrombin and fibrin monomers without allowing polymerization, thereby mediating the suppression of thrombosis while preserving hemostatic potential through its other intact functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Nonpolymerizable fibrinogen effectively reduces thrombosis risk and thrombus size without compromising hemostatic functions, offering a therapeutic strategy for conditions associated with venous or arterial thrombosis, including cancer, obesity, and metabolic syndrome, and can complement antiplatelet therapies.
Implementation Method 1
Activation of coagulation results in thrombin-mediated cleavage of monomeric fibrinogen to fibrin that self-polymerizes to form a fibrin matrix
Data Source
AI summary
This invention relates to methods for inhibiting or reducing the risk of thrombosis or reducing the size and number of thrombi without compromising hemostasis using a nonpolymerizable fibrinogen that is insensitive to thrombin cleavage. Methods and compositions for reducing a required dose or complementing the effect of an antithrombotic agent in the treatment of thrombosis are also provided.